Table 5.

Comparison of incidence of selected nonhematological toxicities among patients with and without DS randomized to MTX regimens

PO MTXIV MTXDS patientsNon-DS patients
DS, %Non-DS, %PDS, %Non-DS, %PPO, %IV, %PPO, %IV, %P
ALT (grades 3/4)
 IM #116.317.1.7012.97.6.4816.312.9.6917.17.6<.001
 IM #27.513.9.406.98.6.847.56.9.6613.98.6.001
Infection with neutropenia (grades 3/4)
 IM #14.72.6.4302.3.394.70.222.62.3.66
 IM #25.03.9.7201.5.5150.223.91.5.001
Leukoencephalopathy (all grades)
 IM #100.2.9600.4.94000.20.4.61
 IM #200.1.8400.5.93000.10.5.25
Mucositis (grades 3/4)
 IM #12.30.6.3029.03.4<.0012.329.0.0040.63.4<.001
 IM #2100.6<.00127.64.1<.0011027.6.130.64.1<.001
Seizures (all grades)
 IM #100.1.833.21.2.5503.2.240.11.2.02
 IM #200.1.8400.8.89000.10.8.05
  • —, not calculated; ALT, alanine aminotransferase.